Associate Professor Kieran Scott

Associate Professor Kieran Scott

Associate Professor, Medical Oncology,
School of Medicine



  • PhD The Australian National University

Organisational Unit (School / Division)

  • School of Medicine


Location: Campbelltown

PLEASE NOTE: obtaining information from this Directory must be for the legitimate purposes of doing business with and within Western Sydney University, and must not be used for unsolicited bulk e-mailing (spamming) or similar purposes.


Chapters in Books

  • Gano, C., Scott, K., Bucci, J., Greenfield, H., Dong, Q. and de Souza, P. (2012), 'Dietary manipulation for therapeutic effect in prostate cancer', Cancer Prevention: From Mechanisms to Translational Benefits, In-Tech 9789535105473.

Journal Articles

  • Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K., Vafaee, F., Scott, K., Roberts, T., Becker, T. and Souza, P. (2022), 'Harnessing liquid biopsies to guide immune checkpoint inhibitor therapy', Cancers, vol 14, no 7 .
  • Khan, T., Becker, T., Scott, K., Descallar, J., Souza, P., Chua, W. and Ma, Y. (2022), 'Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer : a systematic review and meta-analysis', Frontiers in Oncology, vol 12 .
  • Khoury, A., Sakoff, J., Gilbert, J., Scott, K., Karan, S., Gordon, C. and Aldrich-Wright, J. (2022), 'Cyclooxygenase-inhibiting platinum(IV) prodrugs with potent anticancer activity', Pharmaceutics, vol 14, no 4 .
  • Garrett, C., Becker, T., Lynch, D., Po, J., Xuan, W., Scott, K. and Souza, P. (2021), 'Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome', PLoS One, vol 16, no 6 .
  • Powter, B., Jeffreys, S., Sareen, H., Cooper, A., Brungs, D., Po, J., Roberts, T., Koh, E., Scott, K., Sajinovic, M., Vessey, J., Souza, P. and Becker, T. (2021), 'Human TERT promoter mutations as a prognostic biomarker in glioma', Journal of Cancer Research and Clinical Oncology, vol 147, no 4 , pp 1007 - 1017.
  • Scott, K., Mann, T., Fatima, S., Sajinovic, M., Razdan, A., Kim, R., Cooper, A., Roohullah, A., Bryant, K., Kanapaddala Gamage, K., Harman, D., Vafaee, F., Graham, G., Church, W., Russell, P., Dong, Q. and Souza, P. (2021), 'Human Group IIA Phospholipase A2 : three decades on from its discovery', Molecules, vol 26, no 23 .
  • Graham, G. and Scott, K. (2021), 'Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs', Inflammopharmacology, vol 29, no 5 , pp 1261 - 1278.
  • Khan, T., Scott, K., Becker, T., Lock, J., Nimir, M., Ma, Y. and Souza, P. (2020), 'The prospect of identifying resistance mechanisms for castrate-resistant prostate cancer using circulating tumor cells : is epithelial-to-mesenchymal transition a key player?', Prostate Cancer, vol 2020 .
  • Kim, R., Chen, Z., Mann, T., Bastard, K., Scott, K. and Church, W. (2020), 'Structural and functional aspects of targeting the secreted human group IIA phospholipase A2', Molecules, vol 25, no 19 .
  • Singh, P., Souza, P., Scott, K., Hall, B., Verma, N., Toh, J., Sajinovic, M. and Spring, K. (2019), 'Biomarkers in immune checkpoint inhibition therapy for cancer patients : what is the role of lymphocyte subsets and PD1/PD-L1?', Translational Medicine Communications, .
  • Kim, R., Malde, A., Nematollahi, A., Scott, K. and Church, W. (2017), 'Molecular dynamics simulations reveal structural insights into inhibitor binding modes and functionality in human Group IIA phospholipase A2', Proteins, vol 85, no 5 , pp 827 - 842.
  • Becker, T., Caixeiro, N., Lim, S., Tognela, A., Kienzle, N., Scott, K., Spring, K. and de Souza, P. (2014), 'New frontiers in circulating tumour cell analysis : a reference guide for bimolecular profiling towards translational clinical use', International Journal of Cancer, .
  • Caixeiro, N., Kienzle, N., Lim, S., Spring, K., Tognela, A., Scott, K., de Souza, P. and Becker, T. (2014), 'Circulating tumour cells : a bona fide cause of metastatic cancer', Cancer and Metastasis Reviews, vol 33, no 2-3 , pp 747 - 756.
  • Graham, G., Davies, M., Day, R., Mohamudally, A. and Scott, K. (2013), 'The modern pharmacology of paracetamol : therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings', Inflammopharmacology, vol 21, no 3 , pp 201 - 232.
  • Lee, L., Bryant, K., Bouveret, R., Lei, P., Duff, A., Harrop, S., Huang, E., Harvey, R., Gelb, M., Gray, P., Curmi, P., Cunningham, A., Church, W. and Scott, K. (2013), 'Selective inhibition of human Ggroup IIA-secreted phospholipase A(2) (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes', Journal of Biological Chemistry, vol 288, no 21 , pp 15269 - 15279.
  • Tse, B., Scott, K. and Russell, P. (2012), 'Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology', Prostate Cancer, vol 2012 .
  • Bryant, K., Bidgood, M., Lei, P., Taberner, M., Salom, C., Kumar, V., Lee, L., Church, W., Courtenay, B., Smart, B., Gelb, M., Cahill, M., Graham, G., McNeil, H. and Scott, K. (2011), 'A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte', The Journal of Biological Chemistry, vol 286, no 4 , pp 2492 - 2503.
  • Scott, K., Sajinovic, M., Hein, J., Nixdorf, S., Galettis, P., Liauw, W., de Souza, P., Dong, Q., Graham, G. and Russell, P. (2010), 'Emerging roles for phospholipase A2 enzymes in cancer', Biochimie, vol 92, no 6 , pp 601 - 610.
  • Dong, Z., Liu, Y., Scott, K., Levin, L., Gaitonde, K., Bracken, R., Burke, B., Zhai, Q., Wang, J., Oleksowicz, L. and Lu, S. (2010), 'Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer', Carcinogenesis, vol 31, no 11 , pp 1948 - 1955.
  • Koelsch, M., Mallak, R., Graham, G., Kajer, T., Milligan, M., Nguyen, L., Newsham, D., Keh, J., Kettle, A., Scott, K., Ziegler, J., Pattison, D., Fu, S., Hawkins, C., Rees, M. and Davies, M. (2010), 'Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations', Biochemical Pharmacology, vol 79, no 8 , pp 1156 - 1164.
  • Nevalainen, T., Kanchanapangka, S., Youngprapakorn, P., Webb, G., Manolis, C. and Scott, K. (2009), 'Phospholipase A2 activity of crocodile serum', Amphibia Reptilia, vol 30, no 1 , pp 119 - 125.
  • Patel, M., Singh, J., Niknami, M., Kurek, C., Yao, M., Lu, S., Maclean, F., King, N., Gelb, M., Scott, K., Russell, P. and Dong, Q. (2008), 'Cytosolic phospholipase A2-alpha : a potential therapeutic target for prostate cancer', Clinical Cancer Research, vol 14, no 24 , pp 8070 - 8079.
  • Nevalainen, T., Graham, G. and Scott, K. (2008), 'Antibacterial actions of secreted phospholipases A2 : review', Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol 1781, no 1-2 , pp 1 - 9.

Other Publications

  • 2011, 'Method of Screening for Inhibitors of SPLA2-IIA', Patent
  • 2004, 'Method of Inhibiting Prostate Cancer Cell Proliferation', Patent
  • 1988, 'Promoter of the nifD Gene of Bradyrhizobium', Patent

Previous Projects

Title: A translational and pharmacokinetic study of a novel, orally-active, targeted treatment for hormone refractory prostate cancer
  • Prostate Cancer Foundation of Australia (ACRG)
Western Researchers: Paul De Souza and Kieran Scott
Years: 2017-07-19 - 2018-12-31
ID: P00021763

Western Sydney University

Locked Bag 1797
Penrith NSW 2751

Tel: +61 2 9852 5222

ABN 53 014 069 881
CRICOS Provider No: 00917k